News | April 23, 2021
Serum not contracted for complete production of COVID vaccine to centre
These media reports are based on incorrect facts and are without any basis.
These media reports are based on incorrect facts and are without any basis.
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
For the full year, standalone gross revenue crossed Rs. 1,700 crore
The company highlighted continued demand strength and pricing resilience despite global disruptions
Transition to a fermentation-based globally integrated CDMO platform
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Subscribe To Our Newsletter & Stay Updated
